
Stephen Lade

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5508278/publications.pdf Version: 2024-02-01



STEDHEN LADE

#	Article	IF	CITATIONS
1	Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood, 2015, 125, 71-81.	1.4	181
2	Update and new approaches in the treatment of Castleman disease. Journal of Blood Medicine, 2016, Volume 7, 145-158.	1.7	79
3	Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma. Oncotarget, 2018, 9, 36126-36136.	1.8	62
4	A Signature Predicting Poor Prognosis in Gastric and Ovarian Cancer Represents a Coordinated Macrophage and Stromal Response. Clinical Cancer Research, 2014, 20, 2761-2772.	7.0	60
5	Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol. Journal of the American Academy of Dermatology, 2008, 59, 589-595.	1.2	45
6	Prolonged survival with the early use of a novel extracorporeal photopheresis regimen in patients with SA©zary syndrome. Blood, 2019, 134, 1346-1350.	1.4	29
7	Role of immunohistochemistry in the era of genetic testing in <i>MYC</i> -positive aggressive B-cell lymphomas: a study of 209 cases. Journal of Clinical Pathology, 2016, 69, 266-270.	2.0	28
8	The efficacy of methotrexate for lymphomatoid papulosis. Journal of the American Academy of Dermatology, 2015, 72, 1088-1090.	1.2	26
9	Epstein–Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship. Modern Pathology, 2021, 34, 2154-2167.	5.5	25
10	Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study. Blood, 2019, 134, 756-756.	1.4	24
11	Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer. PLoS ONE, 2017, 12, e0183891.	2.5	19
12	Mycosis fungoides and <scp>S</scp> ézary syndrome: Current challenges in assessment, management and prognostic markers. Australasian Journal of Dermatology, 2016, 57, 182-191.	0.7	18
13	Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with <scp>BCR</scp> signalling inhibitors. British Journal of Haematology, 2017, 177, 324-328.	2.5	12
14	Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement. Leukemia and Lymphoma, 2017, 58, 996-998.	1.3	12
15	SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence. Gastric Cancer, 2021, 24, 589-601.	5.3	12
16	A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset of NUTM1-rearranged tumors. Laboratory Investigation, 2021, 101, 26-37.	3.7	12
17	Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target. British Journal of Haematology, 2021, 195, 113-118.	2.5	8
18	The importance of differentiating between mycosis fungoides with CD30-positive large cell transformation and mycosis fungoides with coexistent primary cutaneous anaplastic large cell lymphoma. Journal of the American Academy of Dermatology, 2021, 84, 185-187.	1.2	7

STEPHEN LADE

#	Article	IF	CITATIONS
19	Safety and Efficacy of Ibrutinib in Combination with Venetoclax in Patients with Marginal Zone Lymphoma: Preliminary Results from an Open Label, Phase II Study. Blood, 2019, 134, 3999-3999.	1.4	6
20	Cutaneous CD30 positive lymphoproliferative disorders with coexistent epithelial neoplasms: Report of two cases. Australasian Journal of Dermatology, 2015, 56, e83-e87.	0.7	5
21	CD10 and Das1: a biomarker study using immunohistochemistry to subtype gastric intestinal metaplasia. BMC Gastroenterology, 2022, 22, 197.	2.0	5
22	Mycosis fungoides and Sézary syndrome: Australian clinical practice statement. Australasian Journal of Dermatology, 2021, 62, e8-e18.	0.7	4
23	Two cases of acquired perforating dermatosis successfully treated with allopurinol. Australasian Journal of Dermatology, 2021, , .	0.7	2
24	Response to everolimus in a patient with refractory HGBL-NOS harboring multiple genomic aberrations in PTEN. Leukemia and Lymphoma, 2021, , 1-5.	1.3	1
25	Defining double-hit lymphoma in the clinic. Blood, 2021, 137, 2132-2133.	1.4	0